Pfizer Oncology Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017

The abstracts titles will be publicly released on Thursday, April 20 and the embargo on most data will lift on Wednesday, May 17, at 5:00 p.m. EDT unless otherwise noted.

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2017, multiple abstracts will be presented highlighting clinical progress for 15 Pfizer Oncology assets. The presentations span multiple tumor types and mechanisms of action.

Avelumab:

(Abstract 4504) First-line Avelumab + Axitinib Therapy In Patients With Advanced Renal Cell Carcinoma (aRCC): Results From A Phase 1b Trial. Choueiri TK. Monday, June 5. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Hall B1.

(Abstract 3059) Safety Profile Of Avelumab In Patients With Advanced Solid Tumors: A JAVELIN Pooled Analysis Of Phase 1 And 2 Data. Kelly K. Monday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract 4528) Updated Efficacy And Safety Of Avelumab In Metastatic Urothelial Carcinoma: Pooled Analysis From 2 Cohorts Of The Phase 1b JAVELIN Solid Tumor Study. Apolo AB. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract 9086) Exposure–response and PD-L1 Expression Analysis Of Second-Line Avelumab In Patients With Advanced NSCLC: Data From The JAVELIN Solid Tumor Trial. Gulley JL. Saturday, June 3. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract 9530) First-line (1L) Avelumab Treatment In Patients (pts) With Metastatic Merkel Cell Carcinoma (mMCC): Preliminary Data From An Ongoing Study. D’Angelo S. Saturday, June 3. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract 9557) Exploratory Biomarker Analysis In Avelumab-treated Patients With Metastatic Merkel Cell Carcinoma Progressed After Chemotherapy. Shapiro I. Saturday, June 3. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract TPS4594) Avelumab Plus Axitinib Vs Sunitinib As First-Line Treatment Of Advanced Renal Cell Carcinoma: Phase 3 Study (JAVELIN Renal 101). Choueiri TK. Sunday, June 4. CDT. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract TPS6093) JAVELIN Head and Neck 100: A Phase 3 Trial Of Avelumab In Combination With Chemoradiotherapy (CRT) vs CRT For 1st-Line Treatment Of Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (LA SCCHN). Lee NY. Monday, June 5. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: TBD.
(Abstract TPS7575) Phase 1b/3 Study Of Avelumab-Based Combination Regimens In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Chen R. Monday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract TBD) Avelumab In Metastatic Castration-Resistant Prostate Cancer (mCRPC). Fakhrejahani F. TBD. Poster Session. Presentation Time: TBD. Location: TBD. Poster Board: TBD.

(Abstract e20581) Comparative Study Of Two PD-L1 Expression Assays In Patients With NSCLC. Feng Z. Publication Only.


(Abstract e21070) Non-progression During Avelumab Treatment Is Associated With Clinically Relevant Improvements In Health-Related Quality Of Life In Patients With Merkel Cell Carcinoma. Bharmal M. Publication Only.

Axitinib:

(Abstract 2551) Axitinib Plus Crizotinib In Patients With Advanced Solid Tumors And Metastatic Renal Cell Carcinoma (mRCC): Preliminary Phase 1b Results. Michaelson MD. Monday, June 5. Session Type: Poster Session. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract TPS4597) Phase 3 KEYNOTE-426 Trial: Pembrolizumab (Pembro) Plus Axitinib Versus Sunitinib Alone In Treatment-Naive Advanced/Metastatic Renal Cell Carcinoma (mRCC). Rini B. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

Bosutinib:

(Abstract 7002) Bosutinib (BOS) VS Imatinib (IM) For Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results From The BFORE Trial. Cortes J. Tuesday, June 6. Session Type: Oral. Presentation Time: 9:45 a.m. – 12:45 p.m. CDT. Location: E450ab.

Crizotinib:

(Abstract 2552) Safety And Pharmacokinetics Of Crizotinib In Patients (Pts) With Hepatic Impairment (HI) And Advanced Cancer. El Khoueiry A. Monday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

Dacomitinib:

(Abstract LBA9007) Dacomitinib Versus Gefitinib For The First-Line Treatment Of Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (ARCHER 1050): A Randomized, Open-Label Phase 3 Trial. Mok T. Tuesday, June 6. Session Type: Oral. Presentation Time: 9:45 a.m. – 12:45 p.m. CDT. Location: Hall D1. (Embargoed until Monday, June 5 at 6:30 a.m. CDT)
**Enzalutamide:**

(Absent 5004) A Phase 4, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Continued Enzalutamide (ENZA) Post Prostate-Specific Antigen (PSA) Progression in Men with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC). Attard G. Saturday, June 3. Session Type: Oral. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall B1.

(Absent 1089) Overall Survival (OS) In Patients (Pts) With Diagnostic Positive (Dx+) Breast Cancer: Subgroup Analysis From A Phase 2 Study Of Enzalutamide (ENZA), An Androgen Receptor (AR) Inhibitor, In AR+ Triple-Negative Breast Cancer (TNBC) Treated With 0-1 Prior Lines Of Therapy. Traina T. Sunday, June 4. Session Type: Poster Session. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Absent 5022) Development And Validation Of A Prognostic Model For Overall Survival In Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) From The Phase 3 PREVAIL Clinical Trial. Armstrong A. Monday June 5. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: TBD.

(Absent TPS5097) A Randomized Study Of Enzalutamide In Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT). Shore N. Monday June 5. Session Type: Poster Session. Presentation Time: 1:15 p.m. – 4:45 p.m. CDT. Location: Hall A. Poster Board: TBD.

(Absent e12576) Treatment Patterns And Associated Adverse Events Among Patients With Metastatic Triple-Negative Breast Cancer. Kaklamani V. Publication Only.


(Absent e16524) Hospital Admissions (HA) Among Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Newly Treated With Enzalutamide (ENZA) Or Abiraterone (ABI). Quek R. Publication Only.


**Inotuzumab:**


(Absent e18500) Hospitalization For Patients In The United States (US) And European Union (EU) Treated With Inotuzumab Ozogamicin (InO) VS Standard Of Care (SOC) For Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) In A Global Phase 3 Trial. Su Y. Publication Only.
(Abstract e18504) Cost of Care For Adult Patients With Relapsed Acute Lymphoblastic Leukemia (rALL). Su Y. Publication Only.


**Lorlatinib:**


**Palbociclib:**

(Abstract 1001) Overall Survival Results From The Randomized Phase 2 Study Of Palbociclib (P) In Combination With Letrozole (L) VS Letrozole Alone For First-Line Treatment Of ER+/HER2– Advanced Breast Cancer (PALOMA-1; TRIO-18). Finn RS. Saturday, June 3. Session Type: Oral. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall D1.

(Abstract 1039) Palbociclib (PAL) + Letrozole (L) As First-line (1L) Therapy (TX) In Estrogen Receptor–positive (ER+)/Human Epidermal Growth Factor Receptor 2–negative (HER2-) Advanced Breast Cancer (ABC): Efficacy And Safety Across Patient (Pt) Subgroups. Finn RS. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #31

(Abstract 1050) Predictors Of Prolonged Benefit From Palbociclib (PAL) Plus Fulvestrant (F) In Women With Endocrine-Resistant Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–negative (HR+/HER2–) Advanced Breast Cancer (ABC) In PALOMA-3. Cristofanilli M. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract 1053) Palbociclib Exposure-Response Analyses In Second-Line Treatment Of Hormone-receptor Positive Advanced Breast Cancer. Sun W. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(Abstract 1058) Experience Of Implementing A Novel Random Sampling BICR Audit For Investigator (INV) Assessed Progression Free Survival (PFS) In The PALOMA-3 Trial. Huang X. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

(abstract e12534) Safety Results Of The Canadian Expanded Access Program (EAP) Of Palbociclib In Combination With Letrozole As Treatment Of Postmenopausal Women With Hormone-Receptor-Positive (HR+), HER2-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Who Were Appropriate Candidates For First-Line Endocrine Therapy With Letrozole. Joy AA. Publication Only.

(abstract e13096) Identifying Patients According To Breast Cancer Stage And ER/HER2 Receptor Status Using Claims Data. De Luise C. Publication Only.

(abstract e17526) Patterns of HPV Testing And Treatment Decision In Patients With SCCHN. Zanotti G. Publication Only.
Pan-RCC

(Abstract 4583) Impact of Geographic Region On Overall Survival (OS) In Patients with Metastatic Renal Cell Carcinoma (mRCC): Results From A Pooled Clinical Trials Database. Fay AP. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

Sunitinib

(Abstract 4508) Phase 3 Trial Of Adjuvant Sunitinib In Patients With High-Risk Renal Cell Carcinoma (RCC): Validation Of The 16-gene Recurrence Score In Stage III Patients. Escudier B. Monday, June 5. Session Type: Oral. Presentation Time: 8:00 a.m. – 11:00 a.m. CDT. Location: Arie Crown Theater.

(Abstract 4584) Sunitinib In Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According To IMDC Risk Group. Rini B. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

Talazoparib

(Abstract 1007) Final Results Of A Phase 2 Study of Talazoparib (TALA) Following Platinum or Multiple Cytotoxic Regimens In Advanced Breast Cancer Patients (Pts) With Germline BRCA1/2 Mutations (ABRAZO). Turner NC. Saturday, June 3. Session Type: Oral. Presentation Time: 1:15 p.m. – 4:15 p.m. CDT. Location: Hall D1.

Early-Pipeline Assets

EFNA4 ADC (PF-06647263):

(Abstract 2511) A Phase 1 Study of PF06647263 A Novel EFNA4ADC, In Patients With Metastatic Triple Negative Breast Cancer. Garrido-Laguna I. Monday, June 5. Session Type: Poster Discussion. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion Time: 11:30 a.m. – 12:45 p.m. Location: Arie Crown Theater. Poster Board: TBD.

Gedatolisib:

(Abstract TPS 1113) Phase 1b Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer. Forero-Torres A. Sunday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

Glasdegib:

(Abstract 7061) Phase I/II Trial Of Glasdegib In Patients With Primary Or Secondary Myelofibrosis. Gerds A. Monday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

**OX40 MAb (PF-04518600):**

(Abstract 3027) The Relationship Of Pharmacodynamics (PD) And Pharmacokinetics (PK) To Clinical Outcomes In A Phase I Study Of OX40 Agonistic Monoclonal Antibody (mAb) PF04518600 (PF8600). El Khoueiry A. Monday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: TBD.

###